Gilead Sciences Inc
GILD34.SA
| Exchange: | SA |
| Currency | Brazilian real |
| Fiscal Year End: | December |
| Sector: | Healthcare |
| Industry: | Drug Manufacturers - General |
| Gic Sector: | Health Care |
| Gic Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| Gic Industry: | Pharmaceuticals |
| Gic Sub Industry: | Pharmaceuticals |
| Home Category: | BDR |
| Is Delisted: | False |
| Description: | Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and Am Bisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California. |
| Address: | 333 Lakeside Drive, Foster City, CA, United States, 94404 |
| Website: | https://www.gilead.com |
| Full Time Employees: | 18000 |
| Updated On: | 2024-11-09 |
Highlights
| Market Capitalization: | 697445384192 |
| Market Capitalization Mln: | 697445.38 |
| EBITDA: | 14053000192 |
| PE Ratio: | 1115.52 |
| PEG Ratio: | 0.52 |
| Book Value: | 14.75 |
| Dividend Share: | 3.06 |
| Dividend Yield: | 0.02 |
| Earnings Share: | 0.25 |
| Most Recent Quarter: | 2024-06-30 |
| Operating Margin TTM: | 0.42 |
| Return On Assets TTM: | 0.12 |
| Revenue TTM: | 28298999808 |
| Revenue Per Share TTM: | 22.70 |
| Quarterly Revenue Growth YOY: | 0.07 |
| Gross Profit TTM: | 21624000000 |
| Diluted Eps TTM: | 0.25 |
| Quarterly Earnings Growth YOY: | -0.42 |
Valuation
| Trailing PE: | 1115.52 |
| Forward PE: | 13.38 |
| Price Sales TTM: | 24.55 |
| Price Book MRQ: | 6.63 |
| Enterprise Value: | 802273155060 |
| Enterprise Value Revenue: | 4.97 |
| Enterprise Value Ebitda: | 121.88 |
Shares
| Shares Outstanding: | 2492000000 |
| Shares Float: | 1243632600 |
Technicals
| Beta: | 0.19 |
| 52 Week High: | 279 |
| 52 Week Low: | 161.15 |
| 50 Day MA: | 236.08 |
| 200 Day MA: | 197.76 |
Splits & Dividends
| Forward Annual Dividend Rate: | 5.87 |
| Forward Annual Dividend Yield: | 0.02 |
| Payout Ratio: | 23.96 |
| Ex Dividend Date: | 2024-09-12 |